Table 2 Safety evaluation
From: The low-dose colchicine in patients after non-CABG cardiac surgery: a randomized controlled trial
Variable | Colchicine (n = 65)* | Placebo (n = 62) | P value | |
|---|---|---|---|---|
Adverse outcomes (n, %) | ||||
 30-day mortality | 0 | 0 | – | |
 MV > 48 h | 0 | 0 | – | |
 Cardiac re-operation | 0 | 0 | – | |
 ECMO use | 0 | 0 | – | |
 IABP use | 0 | 0 | – | |
 Stroke | 0 | 0 | – | |
 CRRT use | 0 | 0 | – | |
PPS within POD14 (n, %) | 2, 3.08% | 11, 17.74% | 0.006 | |
Fever beyond first postoperative week | 1, 1.54% | 4, 6.45% | 0.155 | |
Pleuritic chest pain | 0 | 4, 6.45% | 0.037 | |
Friction rub | 1, 1.54% | 7,11.29% | 0.030 | |
Pleural effusion | 1, 1.54% | 11, 17.74% | 0.002 | |
New or worsening pericardial effusion | 0 | 0 | – | |
Other outcomes (n, %) | ||||
 Infection | 2, 3.08% | 3, 4.84% | 0.610 | |
 Cardiac tamponade | 0 | 0 | – | |
 Constrictive pericarditis | 0 | 0 | – | |
ECG monitoring in ICU (n, %) | ||||
 Hyperacute T-wave | 2, 3.08% | 6, 9.68% | 0.126 | |
 ST-elevation | 4, 6.16% | 10, 16.13% | 0.073 | |
 Left/right bundle branch block | 2, 3.08% | 6, 9.68% | 0.126 | |
 Atrial fibrillation | 1, 1.54% | 2, 3.23% | 0.531 | |
 Other ventricular arrhythmias | 2, 3.08% | 6, 9.68% | 0.126 | |
Gastrointestinal disturbances (n, %) | 6, 9.23% | 0 | 0.014 | |
Length of ICU stay (days) | 3.0 (2.00–3.0) | 2.0 (2.0–3.0) | 0.112 | |
Length of hospital stay (days) | 15.0 (14.0–18.5) | 16.0 (14.0–17.2) | 0.692 | |
MV time (hours) | 6.0 (4.5–7.5) | 7.0 (4.0–10.1) | 0.156 | |